Skip to main content

Table 2 Comorbidity and multimorbidity prevalence between TOHVHP HCV group and the general population (age and sex standardized to 2011 Ontario population)

From: HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study

Condition

TOHVHP HCV group

General population

HCV:General popn

N = 1209

N = 6045

Prevalence ratio (95% CI)

n

Prevalence (%)

n

Prevalence (%)

 

Acute myocardial infarctiona

< 6

–

< 17

–

–

Asthma

206

19.40

746

14.74

1.32 (1.06–1.64)

Cancer (any)*

83

7.78

241

4.42

1.76 (1.22–2.55)

Cardiac arrhythmia

31

2.60

258

4.19

0.62 (0.37–1.06)

Chronic obstructive pulmonary disease*

97

7.78

137

3.22

2.42 (1.73–3.39)

Congestive heart failure*

46

3.79

122

3.14

1.21 (0.77–1.88)

Chronic coronary syndrome

89

5.61

422

5.79

0.97 (0.68–1.38)

Dementiaa

< 13

–

48

–

–

Diabetes

207

13.27

819

10.07

1.32 (1.06–1.64)

Hypertension

364

24.97

1746

23.14

1.08 (0.91–1.27)

Non psychotic mood and anxiety disorders

330

31.24

805

14.08

2.22 (1.86–2.64)

Other mental illness

157

13.35

308

4.93

2.71 (2.06–3.55)

Osteoporosis

35

3.11

157

3.35

0.93 (0.55–1.58)

Rheumatoid arthritis

22

1.19

55

0.97

1.23 (0.67–2.24)

Renal failure*

87

6.19

97

2.12

2.92 (1.90–4.48)

Stroke*

22

1.72

101

1.83

0.94 (0.49–1.81)

Substance use disorder*

287

32.83

88

1.24

26.50 (18.35–38.27)

Hepatocellular cancera

30

–

<=6

–

–

Liver failure*

71

4.29

38

0.65

6.63 (3.72–11.81)

Liver transplanta

15

–

0

–

–

Multimorbidity (at least two physical conditions)

554

39.20

2053

28.48

1.38 (1.20–1.58)

Physical-mental health multimorbidity

396

32.24

792

11.91

2.71 (2.29–3.20)

  1. a indicate that direct standardization could not be performed due to sparse age-sex cell sizes. In such cases, direct standardization was performed
  2. Note: Prevalences were standardized using the 2011 Ontario Population, the n is the true size from each group
  3. Bold faced font indicates statistically significant at the 0.05 level
  4. *Significant Finding